CA3238805A1 - Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma - Google Patents

Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma Download PDF

Info

Publication number
CA3238805A1
CA3238805A1 CA3238805A CA3238805A CA3238805A1 CA 3238805 A1 CA3238805 A1 CA 3238805A1 CA 3238805 A CA3238805 A CA 3238805A CA 3238805 A CA3238805 A CA 3238805A CA 3238805 A1 CA3238805 A1 CA 3238805A1
Authority
CA
Canada
Prior art keywords
composition
nitroxoline
use according
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3238805A
Other languages
English (en)
French (fr)
Inventor
David Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of CA3238805A1 publication Critical patent/CA3238805A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3238805A 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma Pending CA3238805A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2116743.2 2021-11-19
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment
PCT/GB2022/052933 WO2023089328A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Publications (1)

Publication Number Publication Date
CA3238805A1 true CA3238805A1 (en) 2023-05-25

Family

ID=79163954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3238805A Pending CA3238805A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Country Status (11)

Country Link
US (1) US20250000852A1 (https=)
EP (1) EP4433054A1 (https=)
JP (1) JP2024540439A (https=)
KR (1) KR20240108407A (https=)
CN (1) CN118215479A (https=)
AU (1) AU2022392456A1 (https=)
CA (1) CA3238805A1 (https=)
GB (1) GB202116743D0 (https=)
IL (1) IL312885A (https=)
MX (1) MX2024006105A (https=)
WO (1) WO2023089328A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment
WO2026022492A1 (en) * 2024-07-26 2026-01-29 Healx Limited Nitroxoline for use in the treatment and/or prevention of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
GB202108224D0 (en) * 2021-06-09 2021-07-21 Healx Ltd Treatment

Also Published As

Publication number Publication date
AU2022392456A1 (en) 2024-05-23
WO2023089328A1 (en) 2023-05-25
US20250000852A1 (en) 2025-01-02
JP2024540439A (ja) 2024-10-31
MX2024006105A (es) 2024-05-30
KR20240108407A (ko) 2024-07-09
CN118215479A (zh) 2024-06-18
EP4433054A1 (en) 2024-09-25
IL312885A (en) 2024-07-01
GB202116743D0 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
Gao et al. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis
JP7383488B2 (ja) 結節性硬化症複合体の処置におけるカンナビジオールの使用
Ren et al. Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR
US20250000852A1 (en) Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
US20150164901A1 (en) Compounds, compositions and methods for treating or preventing neurodegenerative disorders
Ding et al. Inhibition of dectin-1 alleviates neuroinflammatory injury by attenuating NLRP3 inflammasome-mediated pyroptosis after intracerebral hemorrhage in mice: preliminary study results
Radin et al. Lucanthone targets lysosomes to perturb glioma proliferation, chemoresistance and stemness, and slows tumor growth in vivo
US20240261276A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
JP2013504550A (ja) 癌細胞アポトーシス
WO2019201280A1 (en) Use of ginsenoside m1 for manufacturing medicament for treating oral cancer
Huang et al. Regulating TKT activity inhibits proliferation of human acute lymphoblastic leukemia cells
MX2011001411A (es) Usos farmaceuticos de lanosta-8,24-dien-3-ols.
JP2012041314A (ja) 脳腫瘍治療用キット及び脳腫瘍治療方法
WO2019197632A1 (en) Treatment of fragile x syndrome
TW202038960A (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
KR102141971B1 (ko) 항암용 조성물
Nabiya et al. Identification of Fungal Bioactive Compounds Targeting MMP-9 for Endometriosis-An In silico Approach
WO2024121571A1 (en) Nitroxoline for use in the treatment or prevention of a malignant peripheral nerve sheath tumour
CN108175769A (zh) 土贝母苷甲在制备治疗类风湿性关节炎药物中的应用
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
WO2022175671A1 (en) Trifluoperazine for use in the treatment of neurobéastoma
WO2026065486A1 (zh) Quisinostat在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
WO2022175670A1 (en) Lovastatin for use in the treatment of neuroblastoma
WO2026065490A1 (zh) Mitoxantrone在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251103